By [Your Name/News Desk]
In the landscape of modern oncology, few voices resonate with as much authority and lived experience as those at the helm of METAvivor Research and Support. This month, Dr. Kelly Shanahan, President of METAvivor and a retired obstetrician-gynecologist living with Stage IV breast cancer, provided a comprehensive update on the organization’s recent high-level advocacy efforts and personal milestones. Her journey through the month—spanning from the corporate boardrooms of San Francisco to the emotional community hubs of Philadelphia—underscores a pivotal moment in the fight for metastatic breast cancer (MBC) visibility and funding.
Main Facts: A Dual Mission of Advocacy and Personal Survival
The core of Dr. Shanahan’s report centers on two primary pillars: the professional advancement of MBC advocacy through strategic partnerships and the personal, clinical success of her own treatment journey.
METAvivor, a non-profit organization uniquely dedicated to funding research for Stage IV metastatic breast cancer, recently played a central role in two major national events. The first was a series of high-level industry exchanges hosted by Genentech in San Francisco, aimed at integrating patient perspectives into the drug development lifecycle. The second was the 20th annual Living Beyond Breast Cancer (LBBC) MBC conference in Philadelphia, where the focus shifted from corporate strategy to community support and emotional resilience.
Amidst these professional engagements, Dr. Shanahan shared a critical update regarding her own health. After transitioning to a new clinical trial, recent imaging confirmed that the experimental therapies are effectively targeting her metastases. After only two months, every site of her disease showed a reduction in activity—a significant "win" in the volatile world of metastatic oncology, where treatment resistance is a constant threat.
Chronology: From Industry Insights to Community Connection
The narrative of the month began in San Francisco, a global hub for biotechnology. Dr. Shanahan represented METAvivor at Genentech’s "Insight Exchange" and "Experience Exchange." These forums are designed to break down the silos between pharmaceutical manufacturers and the patients they serve. The Insight Exchange focused specifically on oncology, addressing the nuances of clinical trial design, access to care, and the specific needs of those living with incurable cancer.
The Experience Exchange expanded this scope, bringing together representatives from over 125 organizations. This "A to Z" gathering of disease advocates allowed for cross-pollination of ideas, proving that while the biology of diseases like MBC, cystic fibrosis, or rare autoimmune disorders may differ, the hurdles of advocacy—funding, legislative policy, and patient support—remain universal.
Following the West Coast engagements, the focus shifted to the East Coast. Dr. Shanahan and seven other METAvivor board members converged in Philadelphia for the 20th LBBC MBC Conference. For an organization that often operates via digital platforms like Zoom, this gathering represented a rare and vital opportunity for face-to-face collaboration. Board members AJ, Alpha, Barbara, Jamil, Janice, Lynda, and Sarah, along with Executive Director Crystal Moore, utilized the conference to strengthen internal ties and engage directly with the patient community.
Supporting Data: The Reality of Metastatic Breast Cancer
The urgency of METAvivor’s work is grounded in sobering statistics. While "Pink Ribbon" awareness campaigns often focus on early detection and survivorship, the reality for the metastatic community is starkly different.
- The Funding Gap: Historically, only 2% to 5% of all breast cancer research funding is dedicated to Stage IV metastatic disease—the only stage that kills. METAvivor was founded specifically to address this disparity, directing 100% of its net proceeds to research that seeks to transition MBC from a terminal diagnosis to a manageable chronic condition.
- Mortality and Incidence: Metastatic breast cancer accounts for nearly all of the approximately 43,000 breast cancer deaths in the United States annually. It is estimated that over 168,000 women (and men) are currently living with MBC in the U.S.
- Clinical Trial Success: Dr. Shanahan’s personal update serves as a data point for the efficacy of modern clinical trials. Her report that "every one of my many metastases are less active" after just 60 days on a trial protocol highlights the potential of targeted therapies and the necessity of patient participation in research.
At the LBBC conference, METAvivor’s presence was anchored by a dedicated booth managed by volunteer Tim Bigelow. The engagement metrics from the booth indicated a high level of interest in peer-to-peer leadership and grant review volunteering, suggesting a growing movement of patients who want to take an active role in the scientific process.
Official Responses and Recognition
The month was also marked by formal recognition of METAvivor’s leadership. Dr. Shanahan and fellow board member Janice Cowden were honored by Living Beyond Breast Cancer as "Changemakers." This award recognizes individuals who have significantly altered the landscape of the breast cancer community through their advocacy, education, and support.
In her response to the recognition, Dr. Shanahan participated in a panel titled "The Emotional Impact of Living Long-term with MBC." Known for her "sciency, evidence-based" approach—a byproduct of her years as an OB/GYN—Dr. Shanahan spoke candidly about the psychological toll of the disease. She addressed the profound loss of her medical career and how advocacy served as a primary coping mechanism.
"Getting involved with MBC advocacy in general, and METAvivor in particular, has really helped me cope with this diagnosis and the loss of my career," Shanahan noted. This sentiment reflects a broader trend in the patient community: the transition from "patient" to "advocate" as a means of reclaiming agency in the face of a terminal prognosis.
The official stance of METAvivor remains focused on the "Take Action" initiative, encouraging patients and supporters to move beyond awareness. By training peer-to-peer leaders and involving patients in the grant review process, the organization ensures that the "patient voice" is not just heard, but is actually directing the flow of research capital.
Implications: The Future of MBC Advocacy and Treatment
The events of the past month have several long-term implications for the MBC community and the broader healthcare sector.
1. The Professionalization of Patient Advocacy
The inclusion of METAvivor in Genentech’s exchanges signals a shift in how pharmaceutical companies view patient groups. No longer seen as merely "end-users," patients are increasingly being treated as strategic partners. This collaboration is likely to lead to clinical trial designs that are more patient-centric, potentially increasing enrollment rates and reducing the "burden of participation" for those who are already dealing with heavy treatment side effects.
2. The Power of "Evidence-Based" Hope
Dr. Shanahan’s success in her current clinical trial is more than a personal victory; it is a validation of the METAvivor mission. By funding research specifically for Stage IV, the organization is helping to produce the very treatments that are now extending the lives of its own leaders. This creates a powerful feedback loop that can inspire donors and researchers alike.
3. Bridging the Emotional and the Scientific
The panel discussion in Philadelphia highlighted an evolving understanding of the MBC patient experience. There is an increasing recognition that "surviving" long-term with a terminal diagnosis requires more than just biological intervention; it requires a robust emotional infrastructure. The push for more peer-to-peer support groups, as discussed at the METAvivor booth, indicates that the future of MBC care will likely be a hybrid of high-tech genomics and high-touch community support.
4. A Call for Sustained Volunteerism
As METAvivor grows, its reliance on a volunteer-driven model (which allows it to maintain its 100% research funding promise) will require a constant influx of new advocates. The interest shown in Philadelphia for grant reviewing and leadership roles suggests that the MBC community is ready to move from the sidelines into the driver’s seat of oncology research.
Conclusion
Dr. Kelly Shanahan’s "exhausted and energized" state is a microcosm of the metastatic breast cancer community’s current status. While the physical and emotional toll of the disease remains immense, the momentum of advocacy and the breakthroughs in clinical research provide a tangible sense of progress.
From the "A to Z" of disease exchanges to the "Changemaker" stage in Philadelphia, the message is clear: the metastatic community is no longer content with being a footnote in the breast cancer narrative. Through organizations like METAvivor, they are redefining what it means to live—and lead—with Stage IV cancer. As Dr. Shanahan continues her clinical trial, her story serves as a beacon of what is possible when science, advocacy, and community converge.
For those looking to contribute to the mission or seek support, METAvivor encourages visiting their Take Action page to learn about volunteer opportunities, grant reviews, and peer-to-peer leadership training.
About the Author
